| Dr Suketu H Nanavati, MD | |
|
2 Village Dr, Cape May Court House, NJ 08210-1939 | |
| (609) 465-7517 | |
| Not Available |
| Full Name | Dr Suketu H Nanavati |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 56 Years |
| Location | 2 Village Dr, Cape May Court House, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1275562811 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 25MA03564300 (New Jersey) | Primary |
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25MA03564300 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Cape Regional Medical Center Inc | Cape may court house, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Suketu Nanavati Md Pa | 6002074440 | 2 |
News Archive
A protein known to be a key player in the development of Parkinson's disease is able to enter and harm cells in the same way that viruses do, according to a Loyola University Chicago Stritch School of Medicine study.
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended September 30, 2011.
Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.
Today MedeAnalytics, a leading provider of healthcare performance management solutions, introduced its new Financial Strategy Analytics solution, a powerful tool that enables hospitals and health systems to proactively manage finances, hone strategic planning, and optimize managed care performance metrics in the context of today's rapidly changing healthcare marketplace.
› Verified 9 days ago
| Entity Name | Cape Cardiology Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073502050 PECOS PAC ID: 1456427517 Enrollment ID: O20090115000196 |
News Archive
A protein known to be a key player in the development of Parkinson's disease is able to enter and harm cells in the same way that viruses do, according to a Loyola University Chicago Stritch School of Medicine study.
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended September 30, 2011.
Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.
Today MedeAnalytics, a leading provider of healthcare performance management solutions, introduced its new Financial Strategy Analytics solution, a powerful tool that enables hospitals and health systems to proactively manage finances, hone strategic planning, and optimize managed care performance metrics in the context of today's rapidly changing healthcare marketplace.
› Verified 9 days ago
| Entity Name | Suketu Nanavati Md Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568600385 PECOS PAC ID: 6002074440 Enrollment ID: O20120215000094 |
News Archive
A protein known to be a key player in the development of Parkinson's disease is able to enter and harm cells in the same way that viruses do, according to a Loyola University Chicago Stritch School of Medicine study.
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended September 30, 2011.
Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.
Today MedeAnalytics, a leading provider of healthcare performance management solutions, introduced its new Financial Strategy Analytics solution, a powerful tool that enables hospitals and health systems to proactively manage finances, hone strategic planning, and optimize managed care performance metrics in the context of today's rapidly changing healthcare marketplace.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Suketu H Nanavati, MD 2 Village Dr, Cape May Court House, NJ 08210-1939 Ph: (609) 465-7517 | Dr Suketu H Nanavati, MD 2 Village Dr, Cape May Court House, NJ 08210-1939 Ph: (609) 465-7517 |
News Archive
A protein known to be a key player in the development of Parkinson's disease is able to enter and harm cells in the same way that viruses do, according to a Loyola University Chicago Stritch School of Medicine study.
Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported preliminary unaudited financial results for the quarter ended September 30, 2011.
Champions Biotechnology, Inc., an oncology drug development company with a predictive translational platform aimed at accelerating the development and enhancing the value of oncology drugs, announced that a Master Service Agreement with Teva Pharmaceutical Industries has been commissioned for the testing of a novel anti-angiogenic compound in the Champions Tumorgraft™ platform.
Today MedeAnalytics, a leading provider of healthcare performance management solutions, introduced its new Financial Strategy Analytics solution, a powerful tool that enables hospitals and health systems to proactively manage finances, hone strategic planning, and optimize managed care performance metrics in the context of today's rapidly changing healthcare marketplace.
› Verified 9 days ago
Dr. Christopher G Zitnay, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 2 Stone Harbor Blvd, Cape May Court House, NJ 08210 Phone: 609-465-2000 | |
Mark Robert Sorensen, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 211 S Main St, Suite 205, Cape May Court House, NJ 08210 Phone: 609-463-0800 Fax: 609-463-0957 | |
Renjy Vattasseril, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 217 N Main St, Suite 102, Cape May Court House, NJ 08210 Phone: 609-536-8010 Fax: 609-536-8053 | |
Sahil R Shaikh, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2 Stone Harbor Blvd, Cape May Court House, NJ 08210 Phone: 609-463-2803 Fax: 609-463-4991 | |
Dr. Holli Ami Barth, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2 Stone Harbor Blvd, Cape May Court House, NJ 08210 Phone: 609-463-2498 | |
Michael N Boriss, DO Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 217 N Main St, Suite 205, Cape May Court House, NJ 08210 Phone: 609-463-2755 Fax: 609-463-2757 |